Abstract:Studies from recent years have identified a diverse population of both bacteria and fungi in the human vagina and several community signatures have emerged that are associated with susceptibility to infectious disease. A healthy vaginal bacterial microbiome is most frequently dominated by Lactobacillus species [1], yet a combination of other genera are isolated in vaginal swabs in both healthy and diseased states. The vaginal fungal mycobiome is dominated by Ascomycota, of which Candida species are the most abundant. Approximately 20% to 30% of healthy human vaginal samples contain detectable Candida at a single time point, with nearly all of those being C . albicans , and 70% of the population is expected to be vaginally colonized with Candida longitudinally [2]. Despite its prevalence in the healthy vaginal mycobiome, C . albicans is the most common causative agent of vulvovaginal candidiasis (VVC), a cause of significant morbidity in the human population. The next most common species implicated in VVC is C . glabrata , while other species including C . lusitaniae , C . tropicalis , C . parapsilosis , and C . krusei are also known to contribute to vaginal infections [3–5]. Non- albicans Candida species are typically more resistant to antifungal drugs than C . albicans [6], complicating therapeutic options and increasing treatment timelines. A disease state is often distinguished by an exaggerated inflammatory response at the vaginal mucosa [3] that leads to vulvar pruritis and erythema [7]. Polymorphic Candida species can initiate the process of filamentation, morphogenesis from single-celled yeast to multicellular hyphae, which is typically accompanied by increased tissue damage and inflammation [8]. Microbial dysbiosis has long been associated with VVC due to the observation that antibiotic usage dramatically increases the risk of onset. This notion has been challenged by several population studies [9,10]; however, other studies have found a close association between Candida and specific bacteria as well as distinct Lactobacillus species that were associated with decreased observation of fungi in samples or symptomatic VVC [11–15]. Taken together, the evidence suggests that specific bacterial species can have complex impacts on fungal burden and symptomatic infection. Shifts in the vaginal microbiome are also associated with other genital tract infections [13,16] including bacterial vaginosis (BV) and aerobic vaginitis (AV), which are characterized by the displacement of Lactobacillus species by other bacteria such as Gardnerella vaginalis , Streptococcus agalactiae , Staphylococcus aureus , Escherichia coli , and Enterococcus faecalis [17]. Both BV and AV are polymicrobial in nature and are associated with concurrent Candida carriage in many cases [18,19]. Mixed vaginitis, which can include BV or AV together with VVC, is particularly difficult to treat, and during late stages of pregnancy can lead to severe adverse maternal and neonatal outcomes [17,20]. Because it is the most abundant fungal genus in the vagina, this review will focus on the interactions between Candida species and the healthy and pathogenic bacteria found in the vaginal environment. These interactions play a significant role in maintaining homeostasis as well as impacting disease pathogenesis in the genital tract (Fig 1).

Vaginal microbiota and gynecological cancers: a complex and evolving relationship

Vaginal and tumor microbiomes in gynecological cancer (Review)

Cervicovaginal and gastrointestinal microbiomes in gynecological cancers and their roles in therapeutic intervention

Insights into Pathogenesis and Therapy

The interplay between human papillomavirus and vaginal microbiota in cervical cancer development

Association between vaginal microbiota and the progression of ovarian cancer

Vaginal microbiome and cervical cancer

Host-vaginal microbiota interaction: shaping the vaginal microenvironment and bacterial vaginosis

Impact of interkingdom microbial interactions in the vaginal tract

The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease

Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value

Gut Microbes in Gynecologic Cancers: Causes or Biomarkers and Therapeutic Potential

The Microbiome and Gynecologic Cancer: Cellular Mechanisms and Clinical Applications

Human papillomavirus and cervical cancer in the microbial world: exploring the vaginal microecology

Host and Microbiome Interplay Shapes the Vaginal Microenvironment

Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights

Highly specific vaginal microbiome signature for gynecological cancers

Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders

Individuality and generality of intratumoral microbiome in the three most prevalent gynecological malignancies: an observational study

The Alterations of Vaginal Microbiome in HPV16 Infection As Identified by Shotgun Metagenomic Sequencing.

Role of Vaginal microbiota and Human Papillomavirus infection in cervical Oncogenesis: where do we stand?